A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma.

Corazzelli, Gaetano; Saggese, Mariangela; Pavone, Vincenzo; Angrilli, Francesco; Zinzani, Pier Luigi; Spina, Michele; Fina, Mariapaola; Crisci, Stefania; Calemma, Rosa; Arcamone, Manuela; Morelli, Emanuela; Galati, Domenico; Frigeri, Ferdinando; Filippi, Rosaria De; Pinto, Antonello

doi:10.1200/jco.2014.32.15_suppl.8566

Search citation statements

Order By: Relevance

Paper Sections

Select...

Letter To the Editor1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2023

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…median PFS. 11 A study of the mTOR inhibitor temsirolimus (25 mg intravenously weekly) and lenalidomide (20 mg/d, days 1-21, 28-day cycles) in 20 patients with cHL refractory to or relapsing after BV reported an 80% ORR and 9.2-month median PFS. 12 Not all lenalidomide combinations have been as promising.…”

Section: Letter To the Editormentioning

confidence: 99%

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Fehniger,

Watkins,

Ezenwajiaku

et al. 2023

haematol

View full text Add to dashboard Cite

show abstract

Section: Letter To the Editormentioning

confidence: 99%

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Fehniger,

Watkins,

Ezenwajiaku

et al. 2023

haematol

View full text Add to dashboard Cite

show abstract

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma

Watkins

Fanale

Bartlett

2018

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias

Tees

Sokol

2016

American Journal of Therapeutics

View full text Add to dashboard Cite

Novel pharmacotherapeutic agents were recently approved for treatment of low-grade B-cell neoplasms, and many other agents are under investigation. Several agents have demonstrated impressive activity in targeting malignant B-cell processes and specific pathways, all with the potential to expand our ability to effectively treat B-cell malignancies. The inhibitors of several cell regulatory proteins, including Bruton tyrosine kinase (Btk), phosphoinositide 3-kinase (PI3-K), B-cell lymphoma/leukemia-2 (Bcl-2), and histone deacetylases, as well as immunomodulatory agents are a few of the many pharmacotherapeutic agents under study. A comprehensive review and assessment is presented of the current pharmacotherapies under investigation targeting B-cell lymphomas and leukemias.

show abstract

A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma.

Cited by 3 publications

References 0 publications

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma

Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias

Contact Info

Product

Resources

About